Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypes
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Introduction: The functional unit of the mammary gland has been defined as the epithelial cell plus its microenvironment, a hypothesis that predicts changes in epithelial cell function will be accompanied by concurrent changes in mammary stroma. To test this hypothesis, the question was addressed of whether mammary stroma is functionally altered by the anti-oestrogen drug tamoxifen. Methods: Forty female rats at 70 days of age were randomised to two groups of 20 and treated with 1.0 mg/kg tamoxifen or vehicle subcutaneously daily for 30 days, followed by a three-day wash out period. Mammary tissue was harvested and effects of tamoxifen on mammary epithelium and stroma determined. Results: As expected, tamoxifen suppressed mammary alveolar development and mammary epithelial cell proliferation. Primary mammary fibroblasts isolated from tamoxifen-treated rats displayed a three-fold decrease in motility and incorporated less fibronectin in their substratum in comparison to control fibroblasts; attributes indicative of fibroblast quiescence. Immunohistochemistry analysis of CD68, a macrophage lysosomal marker, demonstrated a reduction in macrophage infiltration in mammary glands of tamoxifen-treated rats. Proteomic analyses by mass spectrometry identified several extracellular matrix (ECM) proteins with expression levels with tamoxifen treatment that were validated by Western blot. Mammary tissue from tamoxifen-treated rats had decreased fibronectin and increased collagen 1 levels. Further, ECM proteolysis was reduced in tamoxifen-treated rats as detected by reductions in fibronectin, laminin 1, laminin 5 and collagen 1 cleavage fragments. Consistent with suppression in ECM proteolysis with tamoxifen treatment, matrix metalloproteinase-2 levels and activity were decreased. Biochemically extracted mammary ECM from tamoxifen-treated rats suppressed in vitro macrophage motility, which was rescued by the addition of proteolysed collagen or fibronectin. Mammary ECM from tamoxifen-treated rats also suppressed breast tumour cell motility, invasion and haptotaxis, reduced organoid size in 3-dimensional culture and blocked tumour promotion in an orthotopic xenograft model; effects which could be partially reversed by the addition of exogenous fibronectin. Conclusions: These data support the hypothesis that mammary stroma responds to tamoxifen treatment in concert with the epithelium and remodels to a microenvironment inhibitory to tumour cell progression. Reduced fibronectin levels and reduced ECM turnover appear to be hallmarks of the quiescent mammary microenvironment. These data may provide insight into attributes of a mammary microenvironment that facilitate tumour dormancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594 · cited 1×
“In addition, macrophages are implicated in numerous events associated with cancer progression, including enhanced breast tumour cell motility, increased ECM remodeling, and blood vessel development [53-55].”
BackgroundWeaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483 · cited 1×
“In cell culture studies, downregulation of β1 integrin induced invasive fibroblast-like breast tumour cells to revert to polarised cells capable of contributing to acinar-like epithelium in vitro [24].”
BackgroundMolecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299 · cited 1×
“Left inguinal mammary glands (lymph nodes removed) were processed for fibroblast isolation immediately after sacrifice using a protocol provided by Kornelia Polyak which has been previously reported [30].”
MethodRole of tissue stroma in cancer cell invasion
De Wever, O., & Mareel, M. (2003) · The Journal of Pathology · doi:10.1002/path.1398 · Cited by 1,042 · cited 1×
“Early evidence for stromal impact on cancer progression was observed by histological analyses; as wound healing-associated modifications in stroma, termed desmoplasia, were shown to contribute to poor prognosis in many human cancers, including breast, colon and prostate [9-14].”
BackgroundBasement membrane proteoglycans: from cellar to ceiling
Iozzo, R. V. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1702 · Cited by 521 · cited 1×
“These proteoglycans have roles in collagen assembly, fibrosis, wound healing and cancer [63].”
BackgroundNelson, C. M., & Bissell, M. J. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.05.001 · Cited by 332
Schenk, S., Hintermann, E., Bilban, M., Koshikawa, N., Hojilla, C., Khokha, R., & Quaranta, V. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208145 · Cited by 309
Cited by
Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses
Vandenberg, L. N., Colborn, T., Hayes, T. B., Heindel, J. J., Jacobs, D. R., Lee, D.-H., Shioda, T., Soto, A. M., vom Saal, F. S., Welshons, W. V., et al. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1050 · Cited by 3,209
“Tamoxifen was also shown to disrupt tissue organization of the mammary gland, with specific effects on the stroma that may contribute to the observed effects on proliferation of epithelial cells (549, 550).”
Naba, A., Clauser, K. R., Hoersch, S., Liu, H., Carr, S. A., & Hynes, R. O. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014647 · Cited by 1,354
“branes (27–29), mammary gland (30, 31), and cartilage (32).”
BackgroundSchedin, P., & Keely, P. J. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003228 · Cited by 524
Self-citationCuzick, J., Warwick, J., Pinney, E., Duffy, S. W., Cawthorn, S., Howell, A., Forbes, J. F., & Warren, R. M. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr079 · Cited by 405
Extracellular matrix: A gatekeeper in the transition from dormancy to metastatic growth
Barkan, D., Green, J. E., & Chambers, A. F. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.027 · Cited by 377
Tumor-Host Interactions: A Far-Reaching Relationship
McAllister, S. S., & Weinberg, R. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4257 · Cited by 327
Risk determination and prevention of breast cancer
Howell, A., Anderson, A. S., Clarke, R. B., Duffy, S. W., Evans, D. G., Garcia-Closas, M., Gescher, A. J., Key, T. J., Saxton, J. M., & Harvie, M. N. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0446-2 · Cited by 327
O'Brien, J., Lyons, T., Monks, J., Lucia, M. S., Wilson, R. S., Hines, L., Man, Y.-G., Borges, V., & Schedin, P. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090735 · Cited by 288
Self-citationThe evolution of the cancer niche during multistage carcinogenesis
Barcellos-Hoff, M. H., Lyden, D., & Wang, T. C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3536 · Cited by 279
Emerging organoid models: leaping forward in cancer research
Fan, H., Demirci, U., & Chen, P. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0832-4 · Cited by 199
“These results were consistent with the previous clinical finding that increasing fibronectin level was associated with the lower survival rate in BC patients [53, 54].”
ResultCasbas-Hernandez, P., Fleming, J. M., & Troester, M. A. (2011) · BioMed Research International · doi:10.1155/2011/520987 · Cited by 43
“Tamoxifen, a drug that primarily targets ER-positive epithelium, induces changes in mammary stroma leading to suppression of transformed phenotypes [9], and premalignant breast cancer cells placed on a reconstituted physiological basement membrane undergo cell growth arrest and form polarized alveolar”
Background
Metadata
- Authors
- Hattar, R., Maller, O., McDaniel, S., Hansen, K. C., Hedman, K. J., Lyons, T. R., Lucia, S., Wilson, R. S., & Schedin, P.
- Venue
- Breast Cancer Research
- Published
- 2009-01-27
- Volume
- 11
- Issue
- 1
- Pages
- R5-R5
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2091656580
- Cited by
- 66
- References
- 7
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.